Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial

In this EBV DNA-integral randomized trial, adjuvant cisplatin-gemcitabine did not improve 5-year relapse-free survival versus observation among patients with detectable post-radiotherapy plasma EBV DNA (49.3% vs 54.7%; HR 1.09, P=0.75).

J Clin OncolPubMed 29989858DOI 10.1200/JCO.2018.77.7847